Underscoring the lucrative potential for biosimilars, Pfizer (PFE) has accused Johnson & Johnson (JNJ) of using anti-competitive practices to prevent insurers from covering its version of a best-selling J&J medicine.

In a lawsuit filed on Wednesday, Pfizer claims that J&J used various illegal contracting tactics to convince insurers not to cover Inflectra, a biosimilar version of the blockbuster Remicade treatment for rheumatoid arthritis and other diseases. A biosimilar, you may recall, is a nearly identical variant of a brand-name biologic medicine and is expected to provide the same result in patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • If memory serves, J&J outright sued then Abbott and won $1.7 billion USD for infringement on the Remicade patent by the Humira product, It was overturned on appeal but still rather worse tactics than just low sales, I think.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy